CLK1 and colorectal carcinoma: Two kinds of inhibitors, namely, a competitive Clk inhibitor (TG003) and a Clk1/4 selective inhibitor (KH-CB19), were chosen to identify the potential effect of CLASRP on cell growth in CRC cells overexpressing CLASRP.